Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Broadens Technology Deal with BioMerieux to Cancer Diagnostics

NEW YORK, April 5 (GenomeWeb News) - Affymetrix has expanded an existing technology agreement with diagnostics company BioMerieux to include further disease areas, the companies said today.


Under the agreement, BioMerieux, of Marcy L'Etoile, France, has non-exclusive rights to Affymetrix's GeneChip technology, including future improvements, to develop and market in vitro diagnostics for breast cancer. The company also has the option to broaden this agreement to other cancers.


Under an agreement from late 2003, BioMerieux has had the right to use Affy's GeneChip technology to develop tests for virulence factors, bacterial strain typing, sepsis diagnosis, hepatitis C, as well as respiratory and central nervous system infectious panels.


The companies did not disclose financial terms of the new agreement.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.